



Sheet 1 of 1

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 19226/2071 (R-5659)	SERIAL NO. 09/997,936
	APPLICANT Balasubramanian et al.	
	FILING DATE November 30, 2001	GROUP ART UNIT 1646-1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

RECEIVED

FEB 20 2003

TECH CENTER 1600/2900


FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE
<i>MM</i>	1	WO 02/061036A2	08/08/02	PCT		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	Abdel H. Mohammed		DATE CONSIDERED 12/15/03
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO.		SERIAL NO.
	19226/2071 (R-5659)		09/997,936
	APPLICANT		
	Balasubramanian et al.		
FILING DATE		GROUP ART UNIT	
November 30, 2001		1646 1653	



RECEIVED
 NOV 19 2002
 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE
Am	1	4,965,344	Oct. 23, 1990	Hermann	530	351	
Am	2	5,474,892	Dec. 12, 1995	Jakob et al.	435	4	
Am	3	5,679,582	Oct. 21, 1997	Bowie et al.	436	518	
Am	4	5,935,810	Aug. 10, 1999	Friedman et al.	435	69.1	
Am	5	5,981,714	Nov. 9, 1999	Cheng et al.	530	388.2	
Am	6	6,348,215 B1	Feb. 19, 2002	Straubinger et al.	424	450	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	Abdel A. Mohamed		DATE CONSIDERED 12/15/03
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT SEP 09 2002 (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO.		SERIAL NO.
	19226/2071 (R-5659)		09/997,936
	APPLICANT		
	Balasubramanian et al.		
FILING DATE		GROUP ART UNIT	
November 30, 2001		1646/1653	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AM	1	5,013,556	05/07/1991	Woodle et al.	424	450	
AM	2	5,952,198	09/14/1999	Chan	435	69.6	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION IF APPROPRIATE
AM	3	WO 99/55306	11/04/1999	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

AM ↑ ↓ AM	1	Tavio et al., "Human Chorionic Gonadotropin in the Treatment of HIV-Related Kaposi's Sarcoma," <u>Eur. J. Cancer</u> , 34(10):1634-1637 (1998)	
	2	Lunardi-Iskandar et al., "Effects of a Urinary Factor From Women in Early Pregnancy on HIV-1, SIV and Associated Disease," <u>Nature Med.</u> , 4(4):428-434 (1998)	
	3	Lee-Huang et al., "Lysozyme and RNases as Anti-HIV Components in β -core Preparations of Human Chorionic Gonadotropin," <u>Proc. Natl. Acad. Sci. USA</u> , 96:2678-2681 (1999)	
	4	Timasheff et al., "Preferential Binding of Solvent Components to Proteins in Mixed Water-Organic Solvent Systems," <u>Biochem.</u> , 7(7):2501-2513 (1968)	
	5	Rariy et al., "Protein Refolding in Predominantly Organic Media Markedly Enhanced by Common Salts," <u>Biotechnol. Bioeng.</u> , 62(6):704-710 (1999)	
	6	Rariy et al., "Correct Protein Folding in Glycerol," <u>Proc. Natl. Acad. Sci. USA</u> , 94:13520-13523 (1997)	
	7	Knubovets et al., "Structure, Thermostability, and Conformational Flexibility of Hen Egg-White Lysozyme Dissolved in Glycerol," <u>Proc. Natl. Acad. Sci. USA</u> , 96:1262-1267 (1999)	
	8	Morozova et al., "Stability of Equine Lysozyme. I. Thermal Unfolding Behaviour," <u>Biophys. Chem.</u> , 41:185-191 (1991)	
	9	Ikeguchi et al., "Evidence for Identity Between the Equilibrium Unfolding Intermediate and a Transient Folding Intermediate: A Comparative Study of the Folding Reactions of α -Lactalbumin and Lysozyme," <u>Biochem.</u> , 25:6965-6972 (1986)	
Abdel A. Mohamed		DATE CONSIDERED 12/15/03	RECEIVED SEP 11 2002

TECH CENTER 1500/2900

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT SEP 09 2002 (use several sheets if necessary) (PTO-1449)	ATTORNEY DOCKET NO.		SERIAL NO.
	19226/2071 (R-5659)		09/997,936
	APPLICANT		
	Balasubramanian et al.		
FILING DATE		GROUP ART UNIT	
November 30, 2001		1646/1653	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRAN- SLATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

✓	10	Luo et al., "The 28-111 Disulfide Bond Constrains the α -Lactalbumin Molten Globule and Weakens Its Cooperativity of Folding," <u>Proc. Natl. Acad. Sci. USA</u> , 96:11283-11287 (1999)
	11	Witzke et al., "Beta-Human Choriogonadotropin Therapy and HIV-Related Kaposi's Sarcoma," <u>Eur. J. Med. Res.</u> , 2:155-158 (1997)
✓	12	"Stability of Protein Pharmaceuticals: Part A: Chemical and Physical Pathways of Protein Degradation," in Ahern, eds., <u>Pharmaceutical Biotechnology</u> , Vol. 2, New York, New York: Plenum Press, pp. vii-xvii (1992)
	13	"Stability of Protein Pharmaceuticals: Part B: <i>In Vivo</i> Pathways of Degradation and Strategies for Protein Stabilization," in Ahern, eds., <u>Pharmaceutical Biotechnology</u> , Vol. 3, New York, New York: Plenum Press, pp. vii-viii (1992)
	14	
	15	
	16	
	17	
Abdel A. Mohamed		DATE CONSIDERED 12/15/03

RECEIVED

SEP 11 2002

TECH CENTER 1600/2900

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO.	SERIAL NO.
	19226/2071 (R-5659)	09/997,936
	APPLICANT	
	Balasubramanian et al.	
	FILING DATE	GROUP ART UNIT
	November 30, 2001	1646 1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT & TRADEMARK DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AM	1	Larner, "The Molecular Pathology of Haemophilia," <u>Quarterly J. Med.</u> , 63(242):473-491 (1987)
	2	Toole et al., "Molecular Cloning of a cDNA Encoding Human Antithaemophilic Factor," <u>Nature</u> , 312:342-347 (1984)
	3	Wood et al., "Expression of Active Human Factor VIII From Recombinant DNA Clones," <u>Nature</u> , 312:330-336 (1984)
	4	Fay, "Factor VIII Structure and Function," <u>Thrombosis and Haemostasis</u> , 70(1):63-67 (1993)
	5	Foster et al., "Factor VIII Structure and Function," <u>Blood Reviews</u> , 3:180-191 (1989)
	6	Yoshimoto et al., "Oxidative Refolding of Denatured/Reduced Lysozyme Utilizing the Chaperone-Like Function of Liposomes and Immobilized Liposome Chromatography," <u>Biotechnol. Prog.</u> , 15:480-487 (1999)
	7	Balasubramanian et al., "Liposomes as Formulation Excipients for Protein Pharmaceuticals: A Model Protein Study," <u>Pharm. Res.</u> , 17(3):344-350 (2000)
	8	Kanaoka et al., "Stabilization of Aerosolized IFN- γ by Liposomes," <u>Int. J. Pharmaceutics</u> , 188:165-172 (1999)
	9	Woodle, "Surface-Modified Liposomes: Assessment and Characterization for Increased Stability and Prolonged Blood Circulation," <u>Chem. Phys. Lipids</u> , 64:249-262 (1993)
	10	Gilbert et al., "Specificity of Phosphatidylserine-Containing Membrane Binding Sites for Factor VIII," <u>J. Biol. Chem.</u> , 267(22):15861-15868 (1992)

EXAMINER

Abdel A. Mohamed

DATE CONSIDERED

12/15/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO.	SERIAL NO.
	19226/2071 (R-5659)	09/997,936
	APPLICANT	
	Balasubramanian et al.	
	FILING DATE	GROUP ART UNIT
	November 30, 2001	1646/1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRAN- SLATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	11	Gilbert et al., "Specific Membrane Binding of Factor VIII is Mediated by O-Phospho-L-Serine, A Moiety of Phosphatidylserine," <u>Biochem.</u> , 32:9577-9587 (1993)
	12	Gilbert et al., "Binding of Human Factor VIII to Phospholipid Vesicles," <u>J. Biol. Chem.</u> , 265(2):815-822 (1990)
	13	Hilbich et al., "Aggregation and Secondary Structure of Synthetic Amyloid β A4 Peptides of Alzheimer's Disease," <u>J. Mol. Biol.</u> , 218:149-163 (1991)
	14	Hammarström et al., "Structural Mapping of an Aggregation Nucleation Site in a Molten Globule Intermediate," <u>J. Biol. Chem.</u> , 274(46):32897-32903 (1999)
	15	Tsai et al., "Formulation Design of Acidic Fibroblast Growth Factor," <u>Pharmaceutical Res.</u> , 10(5):649-659 (1993)
	16	Carpenter et al., "Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice," <u>Pharmaceutical Res.</u> , 14(8):969-975 (1997)
	17	Foster et al., "Synthetic Factor VIII Peptides With Amino Acid Sequences Contained Within the C2 Domain of Factor VIII Inhibit Factor VIII Binding to Phosphatidylserine," <u>Blood</u> , 75(10):1999-2004 (1990)
	18	Kalafatis et al., "Factor Va-Membrane Interaction is Mediated by Two Regions Located on the Light Chain of the Cofactor," <u>Biochem.</u> , 33:486-493 (1994)
	19	Lecompte, et al. "Electrostatic and Hydrophobic Interactions Are Involved in Factor Va Binding to Membranes Containing Acidic Phospholipids," <u>J. Biol. Chem.</u> , 269(3):1905-1910 (1994)
	20	Saenko et al., "A Mechanism for Inhibition of Factor VIII Binding to Phospholipid by von Willebrand Factor," <u>J. Biol. Chem.</u> , 270(23):13826-13833 (1995)
EXAMINER		DATE CONSIDERED
Abdel A. Mohamed		12/15/03
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 19226/2071 (R-5659)	SERIAL NO. 09/997,936
	APPLICANT Balasubramanian et al.	
	FILING DATE November 30, 2001	GROUP ART UNIT 1646/1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRAN- SLATION IF APPRO- PRIATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

21	Scandella et al., "In Hemophilia A and Autoantibody Inhibitor Patients: The Factor VIII A2 Domain and Light Chain Are Most Immunogenic," <u>Thrombosis Res.</u> , 101:377-385 (2001)
22	Woodle et al., "Versatility in Lipid Compositions Showing Prolonged Circulation with Sterically Stabilized Liposomes," <u>Biochimica et Biophysica Acta</u> , 1105:193-200 (1992)
23	Klibanov et al., "Amphipathic Polyethyleneglycols Effectively Prolong the Circulation Time of Liposomes," <u>FEBS Letters</u> , 268:235-237 (1990)
24	Papahadjopoulos et al., "Sterically Stabilized Liposomes: Improvements in Pharmacokinetics and Antitumor Therapeutic Efficacy," <u>Proc. Natl. Acad. Sci. USA</u> , 88:11460-11464 (1991)
25	Lasic et al., "Sterically Stabilized Liposomes: A Hypothesis on the Molecular Origin of the Extended Circulation Times," <u>Biochimica et Biophysica Acta</u> , 1070:187-192 (1991)
26	Pan et al., "Proposed Structure of the A Domains of Factor VIII by Homology Modelling," <u>Nature Structural Biol.</u> , 2(9):740-744 (1995)
27	Purohit et al., "Mutants of Human Choriogonadotropin Lacking N-Glycosyl Chains in the α -Subunit. 1. Mechanism for the Differential Action of the N-Linked Carbohydrates," <u>Biochem.</u> , 36:12355-12363 (1997)
28	Aloj et al., "Interaction of 1, 8-ANS With Human Luteinizing Hormones: A Probe for Subunit Interactions of hCG and hLH," <u>Archives of Biochem. and Biophysics</u> , 165:478-479 (1973)
29	Balasubramanian et al., "Interferon- γ -Inhibitory Oligodeoxynucleotides Alter the Conformation of Interferon- γ ," <u>Molecular Pharmacol.</u> , 53:926-932 (1998)
30	Lakowicz, <u>Principles of Fluorescence Spectroscopy, Second Edition</u> , New York, New York: Plenum Publishers, pp. 51-54 (1999)

EXAMINER


Abdel A. Mohamed

DATE CONSIDERED

12/15/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO.	SERIAL NO.
	19226/2071 (R-5659)	09/997,936
	APPLICANT	
	Balasubramanian et al.	
	FILING DATE	GROUP ART UNIT
	November 30, 2001	1646-1653



RECEIVED

APR 29 2002

TECH CENTER 1600/2900



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRAN- SLATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	31	Ptitsyn et al., "Evidence For a Molten Globule State as a General Intermediate in Protein Folding," <u>FEBS. Letters</u> , 262(1):20-24 (1990)
EXAMINER		
	DATE CONSIDERED 12/15/03	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		